Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

LGND 49.17 -2.00 (-3.91%)
price chart
Lemeson Ups Ligand Pharmaceuticals Inc. (LGND) Short
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and appended with additional concerns its initial June 16, 2014 research ...
Ligand Pharmaceuticals: Appendix  Seeking Alpha
Related articles »  
Ligand Pharmaceuticals Inc.: Ligand Chairman Dr. John W. Kozarich Named ...
Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum ...
Related articles »  
Ligand Reports Second Quarter Revenues and Announces Share Repurchase ...
"We are pleased with the financial performance of all aspects of our business and to be reporting second quarter revenues that are meaningfully above our previous guidance," said Nishan de Silva, Chief Financial Officer of Ligand Pharmaceuticals, Inc ...
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7%  Zacks.com
Related articles »  
Ligand Pharmaceuticals Coverage Initiated at Empire Asset Management (LGND)
Ligand Pharmaceuticals Inc. logo Equities research analysts at Empire Asset Management assumed coverage on shares of Ligand Pharmaceuticals (NASDAQ:LGND) in a research note issued to investors on Tuesday.
Related articles »  
Biotech Decliners: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Ligand ...
Beta of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is 1.26. Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, on 15 July announced the signing of a platform technology license ...
Related articles »  
Ligand Pharma (LGND) Prelim. Q2 Revs Top Views; Approves $10M Buyback
�We are pleased with the financial performance of all aspects of our business and to be reporting second quarter revenues that are meaningfully above our previous guidance,� said Nishan de Silva, Chief Financial Officer of Ligand Pharmaceuticals, Inc ...
Biotech Insider Buying: bluebird bio (NASDAQ:BLUE), Ligand Pharmaceuticals ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Chief Operating Officer & Executive Vice President Matthew W. Foehr acquired 428shares of bluebird bio stock in a transaction that occurred on Monday, June 30.
New Market Research Report: Ligand Pharmaceuticals, Inc. - Product Pipeline ...
This report provides comprehensive information on the current therapeutic developmental pipeline of Ligand Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), ...
Related articles »  
Ligand: Pipeline Breakdown Reveals Bullish Outlook
In fact, I believe that the number of collaborations Ligand has acquired astounding, considering that 90 collaborations is more consistent with the capacity of major pharmaceutical companies, not a company like Ligand which has a sub $2 billion market cap.
Biggest Movers in Healthcare Stocks Now � HALO TRNX LGND
Wellcare Group (WCG): WCG stock is down 4.3% today. Tornier N.V. (TRNX): TRNX stock is down 4.0% today. Ligand Pharmaceuticals Inc (LGND): LGND stock is down 3.9% today and down 21.5% in the last month. Acadia Healthcare Company Inc (ACHC): ...